@article{article, title = {{DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2022}}, month = {{2}}, author = {{McBride SM and Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Bracken K and Roncolato FT and Horvath L and Sengupta S and Martin J et al}}, doi = {{10.1200/jco.2022.40.6_suppl.tps284}}, volume = {{40}}, journal = {{Journal of Clinical Oncology}}, issue = {{6_suppl}}, pages = {{TPS284-TPS284}}, note = {{Accessed on 2025/05/31}}}